COPD exacerbations and patient-reported outcomes according to post-bronchodilator FEV1 – a post-hoc analysis of pooled data
Background: Management strategies of chronic obstructive pulmonary disease (COPD) need to be tailored to the forced expiratory volume in one second (FEV1), exacerbations, and patient-reported outcomes (PROs) of individual patients. In this study, we analyzed the association and correlation between t...
Published in: | BMC Pulmonary Medicine |
---|---|
Main Author: | |
Format: | Article |
Language: | English |
Published: |
BioMed Central Ltd
2023
|
Online Access: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85156238738&doi=10.1186%2fs12890-023-02436-1&partnerID=40&md5=5100aecb2452fcc12caf59b9a85851d9 |
id |
2-s2.0-85156238738 |
---|---|
spelling |
2-s2.0-85156238738 Chai C.-S.; Ng D.-L.-C.; Bt Mos S.; Ibrahim M.A.B.; Tan S.-B.; Pang Y.-K.; Liam C.-K. COPD exacerbations and patient-reported outcomes according to post-bronchodilator FEV1 – a post-hoc analysis of pooled data 2023 BMC Pulmonary Medicine 23 1 10.1186/s12890-023-02436-1 https://www.scopus.com/inward/record.uri?eid=2-s2.0-85156238738&doi=10.1186%2fs12890-023-02436-1&partnerID=40&md5=5100aecb2452fcc12caf59b9a85851d9 Background: Management strategies of chronic obstructive pulmonary disease (COPD) need to be tailored to the forced expiratory volume in one second (FEV1), exacerbations, and patient-reported outcomes (PROs) of individual patients. In this study, we analyzed the association and correlation between the FEV1, exacerbations, and PROs of patients with stable COPD. Methods: This was a post-hoc analysis of pooled data from two cross-sectional studies that were previously conducted in Malaysia from 2017 to 2019, the results of which had been published separately. The parameters measured included post-bronchodilator FEV1 (PB-FEV1), exacerbations, and scores of modified Medical Research Council (mMRC), COPD Assessment Test (CAT), and St George’s Respiratory Questionnaire for COPD (SGRQ-c). Descriptive, association, and correlation statistics were used. Results: Three hundred seventy-four patients were included in the analysis. The PB-FEV1 predicted was < 30% in 85 (22.7%), 30–49% in 142 (38.0%), 50–79% in 111 (29.7%), and ≥ 80% in 36 (9.6%) patients. Patients with PB-FEV1 < 30% predicted had significantly more COPD exacerbations than those with PB-FEV1 30–49% predicted (p < 0.001), 50–79% predicted (p < 0.001), and ≥ 80% predicted (p = 0.002). The scores of mMRC, CAT, and SGRQ-c were not significantly higher in patients with more severe airflow limitation based on PB-FEV1 (p = 0.121–0.271). The PB-FEV1 predicted had significant weak negative correlations with exacerbations (r = − 0.182, p < 0.001), mMRC (r = − 0.121, p = 0.020), and SGRQ-c scores (r = − 0.114, p = 0.028). There was a moderate positive correlation between COPD exacerbations and scores of mMRC, CAT, and SGRQ-c (r = 0.407–0.482, all p < 0.001). There were significant strong positive correlations between mMRC score with CAT (r = 0.727) and SGRQ-c scores (r = 0.847), and CAT score with SGRQ-c score (r = 0.851) (all p < 0.001). Conclusions: In COPD patients, different severity of airflow limitation was not associated with significant differences in the mMRC, CAT, and SGRQ-c scores. Exacerbations were significantly more frequent in patients with very severe airflow limitation only. The correlation between airflow limitation with exacerbations, mMRC, and SGRQ-c was weak. © 2023, The Author(s). BioMed Central Ltd 14712466 English Article All Open Access; Gold Open Access |
author |
Chai C.-S.; Ng D.-L.-C.; Bt Mos S.; Ibrahim M.A.B.; Tan S.-B.; Pang Y.-K.; Liam C.-K. |
spellingShingle |
Chai C.-S.; Ng D.-L.-C.; Bt Mos S.; Ibrahim M.A.B.; Tan S.-B.; Pang Y.-K.; Liam C.-K. COPD exacerbations and patient-reported outcomes according to post-bronchodilator FEV1 – a post-hoc analysis of pooled data |
author_facet |
Chai C.-S.; Ng D.-L.-C.; Bt Mos S.; Ibrahim M.A.B.; Tan S.-B.; Pang Y.-K.; Liam C.-K. |
author_sort |
Chai C.-S.; Ng D.-L.-C.; Bt Mos S.; Ibrahim M.A.B.; Tan S.-B.; Pang Y.-K.; Liam C.-K. |
title |
COPD exacerbations and patient-reported outcomes according to post-bronchodilator FEV1 – a post-hoc analysis of pooled data |
title_short |
COPD exacerbations and patient-reported outcomes according to post-bronchodilator FEV1 – a post-hoc analysis of pooled data |
title_full |
COPD exacerbations and patient-reported outcomes according to post-bronchodilator FEV1 – a post-hoc analysis of pooled data |
title_fullStr |
COPD exacerbations and patient-reported outcomes according to post-bronchodilator FEV1 – a post-hoc analysis of pooled data |
title_full_unstemmed |
COPD exacerbations and patient-reported outcomes according to post-bronchodilator FEV1 – a post-hoc analysis of pooled data |
title_sort |
COPD exacerbations and patient-reported outcomes according to post-bronchodilator FEV1 – a post-hoc analysis of pooled data |
publishDate |
2023 |
container_title |
BMC Pulmonary Medicine |
container_volume |
23 |
container_issue |
1 |
doi_str_mv |
10.1186/s12890-023-02436-1 |
url |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85156238738&doi=10.1186%2fs12890-023-02436-1&partnerID=40&md5=5100aecb2452fcc12caf59b9a85851d9 |
description |
Background: Management strategies of chronic obstructive pulmonary disease (COPD) need to be tailored to the forced expiratory volume in one second (FEV1), exacerbations, and patient-reported outcomes (PROs) of individual patients. In this study, we analyzed the association and correlation between the FEV1, exacerbations, and PROs of patients with stable COPD. Methods: This was a post-hoc analysis of pooled data from two cross-sectional studies that were previously conducted in Malaysia from 2017 to 2019, the results of which had been published separately. The parameters measured included post-bronchodilator FEV1 (PB-FEV1), exacerbations, and scores of modified Medical Research Council (mMRC), COPD Assessment Test (CAT), and St George’s Respiratory Questionnaire for COPD (SGRQ-c). Descriptive, association, and correlation statistics were used. Results: Three hundred seventy-four patients were included in the analysis. The PB-FEV1 predicted was < 30% in 85 (22.7%), 30–49% in 142 (38.0%), 50–79% in 111 (29.7%), and ≥ 80% in 36 (9.6%) patients. Patients with PB-FEV1 < 30% predicted had significantly more COPD exacerbations than those with PB-FEV1 30–49% predicted (p < 0.001), 50–79% predicted (p < 0.001), and ≥ 80% predicted (p = 0.002). The scores of mMRC, CAT, and SGRQ-c were not significantly higher in patients with more severe airflow limitation based on PB-FEV1 (p = 0.121–0.271). The PB-FEV1 predicted had significant weak negative correlations with exacerbations (r = − 0.182, p < 0.001), mMRC (r = − 0.121, p = 0.020), and SGRQ-c scores (r = − 0.114, p = 0.028). There was a moderate positive correlation between COPD exacerbations and scores of mMRC, CAT, and SGRQ-c (r = 0.407–0.482, all p < 0.001). There were significant strong positive correlations between mMRC score with CAT (r = 0.727) and SGRQ-c scores (r = 0.847), and CAT score with SGRQ-c score (r = 0.851) (all p < 0.001). Conclusions: In COPD patients, different severity of airflow limitation was not associated with significant differences in the mMRC, CAT, and SGRQ-c scores. Exacerbations were significantly more frequent in patients with very severe airflow limitation only. The correlation between airflow limitation with exacerbations, mMRC, and SGRQ-c was weak. © 2023, The Author(s). |
publisher |
BioMed Central Ltd |
issn |
14712466 |
language |
English |
format |
Article |
accesstype |
All Open Access; Gold Open Access |
record_format |
scopus |
collection |
Scopus |
_version_ |
1809678156235276288 |